BGI Genomics(SZ:300676)2022-12-03 09:20Group 1: Genetic Testing Achievements - The non-invasive prenatal testing (NIPT) program in Shenzhen has achieved a coverage rate of approximately 70% in 2017, ranking first among all cities in China [1] - The incidence of Down syndrome in Shenzhen increased from 4.70 per 10,000 in 2011 to 11.64 per 10,000 in 2017, but the live birth rate of Down syndrome infants decreased from 2.36 per 10,000 in 2011 to 0.84 per 10,000 in 2017 due to effective interventions [1] - By December 31, 2017, BGI had provided NIPT services to 312,582 pregnant women in Shenzhen, demonstrating significant effectiveness [1] Group 2: National Firsts and Public Health Impact - Shenzhen's NIPT program is the first to be included in the National Development and Reform Commission's special subsidies for the biotechnology industry [2] - It is also the first to be incorporated into maternity insurance and included in the Shenzhen Maternal and Child Health Handbook as a routine screening project [2] - The program has created opportunities for big data research, enhancing public welfare [2] Group 3: Company Response to Media and Market Concerns - The company clarified its position regarding media reports on "missed tests," stating that the services provided were compliant and accurate within the testing scope [3] - Following media coverage, the company issued a clarification announcement and communicated directly with affected families to provide support and guidance [3] - To stabilize investor confidence, the management team announced a share buyback plan with a total investment of no less than 190 million RMB [2]